# ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma

> **NCT05479708** · — · ACTIVE_NOT_RECRUITING · sponsor: **BAIYONG SHEN** · enrollment: 150 (estimated)

## Conditions studied

- Pancreatic Cancer Resectable

## Interventions

- **DEVICE:** ctDNA-based MRD detection

## Key facts

- **NCT ID:** NCT05479708
- **Lead sponsor:** BAIYONG SHEN
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-09
- **Primary completion:** 2028-01
- **Final completion:** 2028-08
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05479708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05479708, "ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05479708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*